# US 6,297,288 B1 · Method of preventing the effects of altered Δ-5 pathway steroidogenesis in adrenergically blockaded conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,297,288 B1
- Document ID: US6297288B1
- Status: Granted
- Kind: B1
- Application number: 08/781,828
- Filed: 1997-01-10
- Granted: 2001-10-02
- Earliest claimed: 1996-01-11
- Inventors: Robert E. Weinstein
- Web page: https://patentgrep.com/patent/US6297288B1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The production of sex steroids by the Δ-5 steroidogenic pathway has been found to be under control of the adrenergic nervous system, and sex steroids produced by this pathway are diminished in individuals with adrenergically-blockaded conditions. This invention relates to diminishing the consequences of suppressed Δ-5 pathway steroidogenesis in individuals with adrenergically blockaded conditions by the administration of compositions which raise the serum levels of sex steroids.

## Claims

### Claim 1

A method of preventing the effects of suppressed Δ-5 pathway steroidogenesis in an individual with adrenergically blockaded conditions comprising the step of administering an effective amount of adrenergic stimulant to said individual.

### Claim 2

A method to raise the levels of sex steroids produced by the Δ-5 steroidogenic pathway affected by the adrenergic blockade of the Δ-5 steroidogenic pathway in an individual with suppressed Δ-5 pathway steroidogenesis comprising the step of administering an effective amount of adrenergic stimulant to said individual.

### Claim 3 (depends on 2)

A method according to claim 2, wherein the sex steroid is DHEA.

### Claim 4 (depends on 2)

A method according to claim 2, wherein the sex steroid is DHEAS.

### Claim 5 (depends on 2)

A method according to claim 2, wherein the sex steroid is an estrogen.

### Claim 6 (depends on 1)

A method according to claim 1, wherein the adrenergic stimulant is β-agonist.

### Claim 7 (depends on 2)

A method according to claim 2, wherein the adrenergic stimulant is a β-agonist.

### Claim 8 (depends on 6, 7)

A method according to claim 6 or claim 7, wherein the β-agonist is albuteral.

### Claim 9 (depends on 6, 7)

A method according to claim 6 or claim 7, wherein the β-agonist is albuteral administered via the respiratory route.

### Claim 10 (depends on 6, 7)

A method according to claim 6 or claim 7, wherein the Δ-5 agonist is salmeterol xinafoate administered via the respiratory route.